Aaron Amat / Shutterstock.com
By facilitating public access to the work being done, universities face the challenge of maintaining a balance between being transparent and commercialising IP. LSIPR spoke to the head of the University of Manchester IP about walking the fine line.
When it comes to developing and marketing drugs, it is fair to say universities are in a precarious position. Unlike pharmaceutical and biotechnology companies, universities are responsible to research councils and their taxpayer masters to be open about their research.
This can put a strain on protecting research with IP. By having to facilitate public access to the work being done, universities face the challenge of maintaining a balance between transparency and IP protection.
But things have moved beyond basic government demands that research be published and put in the public domain. Now, says Dr Rich Ferrie, head of the University of Manchester IP (UMIP), “research councils that are funding this research want to see that translated into some societal benefit”.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
UMIP; tech transfer; pharmaceuticals; C4X
